Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Macleods Pharmaceuticals

Pharmaceutical intelligence for Macleods Pharmaceuticals with 24 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
15
Catalysts
9
Assets
12

Recent signals(15)

RegulatoryAugust 8, 2026

FDA Grants Supplement Approval for Levothyroxine Sodium by Macleods

The FDA has granted an Abbreviated New Drug Application (ANDA) supplement approval for Levothyroxine Sodium submitted by Macleods Pharmaceuticals.

RegulatoryAugust 8, 2026

FDA Submission Overview for Finerenone by Macleods Pharmaceuticals

Macleods Pharmaceuticals has submitted an application (ANDA220747) for Finerenone, currently under review.

StrategyAugust 8, 2026

FDA Grants Approval for Nintedanib Esylate ANDA219926 by Macleods Pharmaceuticals

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 219926 for Nintedanib Esylate submitted by Macleods Pharmaceuticals.

RegulatoryAugust 8, 2026

FDA Accepts Supplement for Levocetirizine Dihydrochloride by Macleods

The FDA has accepted a supplemental application for Levocetirizine Dihydrochloride submitted by Macleods Pharmaceuticals.

RegulatoryJuly 24, 2026

FDA Accepts Supplement for Rosuvastatin Calcium by Macleods

The FDA has accepted a supplemental application for Rosuvastatin Calcium from Macleods Pharmaceuticals.

StrategyJuly 18, 2026

FDA Accepts ANDA for Choline Fenofibrate by Macleods Pharmaceuticals

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Choline Fenofibrate submitted by Macleods Pharmaceuticals.

StrategyJuly 17, 2026

FDA Grants AP Status for Levothyroxine Sodium ANDA211417

The FDA has granted approval status (AP) for ANDA211417, a generic formulation of Levothyroxine Sodium by Macleods Pharmaceuticals.

RegulatoryJuly 16, 2026

FDA Submission for Finerenone by Macleods Pharmaceuticals

Macleods Pharmaceuticals has submitted an ANDA for Finerenone, currently under review.

StrategyJuly 16, 2026

FDA Grants AP Status for Levocetirizine Dihydrochloride ANDA205564

The FDA has granted Abbreviated Approval (AP) status for ANDA205564, a generic formulation of Levocetirizine Dihydrochloride by Macleods Pharmaceuticals.

RegulatoryJuly 15, 2026

FDA Grants Approval for Dapsone ANDA218335 by Macleods Pharmaceuticals

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 218335 for Dapsone submitted by Macleods Pharmaceuticals.

StrategyJuly 9, 2026

FDA Grants Approval for Chlorthalidone ANDA212229 by Macleods Pharmaceuticals

The FDA has granted approval for the ANDA212229 application for Chlorthalidone submitted by Macleods Pharmaceuticals.

RegulatoryJune 27, 2026

FDA Approves ANDA for Bupropion Hydrochloride by Macleods

The FDA has approved ANDA218567 for Bupropion Hydrochloride submitted by Macleods Pharmaceuticals.

RegulatoryJune 27, 2026

FDA Grants Approval for Rifapentine ANDA217042 by Macleods Pharmaceuticals

The FDA has granted approval for the ANDA217042 application for Rifapentine submitted by Macleods Pharmaceuticals.

StrategyJune 24, 2026

FDA Grants Approval for Tramadol Hydrochloride ANDA209404 by Macleods

The FDA has granted approval for ANDA209404, a supplemental application for Tramadol Hydrochloride by Macleods Pharmaceuticals.

StrategyJune 22, 2026

FDA Grants Approval for Tofacitinib Citrate ANDA219530 by Macleods Pharmaceuticals

The FDA has granted approval for ANDA219530, a generic version of Tofacitinib Citrate, submitted by Macleods Pharmaceuticals.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(8)

RegulatoryAugust 8, 2026

FDA Grants Supplement Approval for Levothyroxine Sodium by Macleods

The FDA has granted an Abbreviated New Drug Application (ANDA) supplement approval for Levothyroxine Sodium submitted by Macleods Pharmaceuticals.

RegulatoryAugust 8, 2026

FDA Submission Overview for Finerenone by Macleods Pharmaceuticals

Macleods Pharmaceuticals has submitted an application (ANDA220747) for Finerenone, currently under review.

RegulatoryAugust 8, 2026

FDA Accepts Supplement for Levocetirizine Dihydrochloride by Macleods

The FDA has accepted a supplemental application for Levocetirizine Dihydrochloride submitted by Macleods Pharmaceuticals.

RegulatoryJuly 24, 2026

FDA Accepts Supplement for Rosuvastatin Calcium by Macleods

The FDA has accepted a supplemental application for Rosuvastatin Calcium from Macleods Pharmaceuticals.

RegulatoryJuly 16, 2026

FDA Submission for Finerenone by Macleods Pharmaceuticals

Macleods Pharmaceuticals has submitted an ANDA for Finerenone, currently under review.

RegulatoryJuly 15, 2026

FDA Grants Approval for Dapsone ANDA218335 by Macleods Pharmaceuticals

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 218335 for Dapsone submitted by Macleods Pharmaceuticals.

RegulatoryJune 27, 2026

FDA Approves ANDA for Bupropion Hydrochloride by Macleods

The FDA has approved ANDA218567 for Bupropion Hydrochloride submitted by Macleods Pharmaceuticals.

RegulatoryJune 27, 2026

FDA Grants Approval for Rifapentine ANDA217042 by Macleods Pharmaceuticals

The FDA has granted approval for the ANDA217042 application for Rifapentine submitted by Macleods Pharmaceuticals.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

Bupropion Hydrochloride →
Chlorthalidone →
Dapsone →
FDA →
Finerenone →
Levocetirizine →
Levothyroxine Sodium →
Nintedanib →
Regulatory Approval →
Rifapentine →
Tofacitinib Citrate →
Tramadol Hydrochloride →

Therapeutic areas

Allergy →
Allergy · Antihistamine →
Antihistamine →
Antimicrobial →
Antitubercular →
Cardiology →
Cardiovascular →
Cardiovascular · Diuretic →
Cardiovascular · Lipid Regulation →
Depression →
Diuretic →
Endocrinology →
Endocrinology · Thyroid Disorders →
Immunology →
Immunology · JAK Inhibitor →
Infectious Disease →
Infectious Disease · Antimicrobial →
Infectious Disease · Antitubercular →
JAK Inhibitor →
Lipid Regulation →
Mineralocorticoid Receptor Antagonist →
Neurology →
Neurology · Depression →
Oncology →
Opioid →
Pain Management →
Pain Management · Opioid →
Small Molecule →
Statin →
Thyroid Disorders →

Indications

Infectious Disease →
Thyroid Disorders →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.